TruBridge, Inc. (TBRG) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The financial performance shows modest growth, with a 2% revenue increase and stable gross margins. However, the sunset of the Centriq product and flat Patient Care revenue are concerns. The Q&A reveals cautious optimism, with improvements in retention and margin expansion opportunities. The lack of a strategic review timeline and unchanged competitive landscape suggest uncertainty. Overall, the sentiment is balanced, with no strong catalysts for significant stock movement.
Key Financial Performance
Total Revenue (Q4 2025) $87.2 million, approximately flat year-over-year. The decline included $1 million from the sunset of the Centriq product in the patient care business. Normalizing for this, revenue growth would have been about 1% higher.
Adjusted EBITDA (Q4 2025) $19.2 million, representing a margin expansion of 160 basis points from 20.4% in Q4 2024 to 22% in Q4 2025. This improvement reflects stronger gross profit performance and cost optimization initiatives.
Total Revenue (Full Year 2025) $346.8 million, a 1.4% increase over 2024. Growth was driven by Financial Health and Encoder businesses, partially offset by client attrition and slower growth in other products.
Adjusted EBITDA (Full Year 2025) $68.7 million, up 23% year-over-year, with a margin expansion of 350 basis points. This was driven by improved productivity, cost actions, and disciplined cost management.
Free Cash Flow (Full Year 2025) $20 million, an increase of $5 million over 2024. This was driven by stronger profitability, improved working capital management, and disciplined expense management.
Cash Flow from Operations (Full Year 2025) $37 million, an increase of 19% year-over-year, driven by stronger profitability and improved working capital management.
Net Debt (End of 2025) $139.8 million, reduced by approximately $19.5 million year-to-date. Net leverage improved to 2x, marking the strongest leverage position in several years.
Bookings (Q4 2025) $19.8 million on a total contract value basis, up $6 million compared to Q4 2024 and up $4 million sequentially. Growth was supported by SaaS, strategic partnerships, and demand for revenue cycle technology.
Bookings (Full Year 2025) $82.9 million on a total contract value basis, up 1% compared to 2024. Annual Contract Value (ACV) bookings were $70.9 million.
Financial Health Revenue (Q4 2025) $56.2 million, approximately 65% of total company revenue, representing a 2% year-over-year increase due to strong growth in the Encoder business.
Patient Care Revenue (Q4 2025) $31 million, a 6.6% year-over-year decline, primarily due to the sunset of the Centriq product.
Financial Health Revenue (Full Year 2025) $221.7 million, up 2% compared to 2024, driven by growth in CBO and Encoder businesses, partially offset by client attrition and slower growth in other products.
Patient Care Revenue (Full Year 2025) $125.2 million, roughly flat versus 2024. Excluding the impact of Centriq, revenue growth would have been about 4%, driven by SaaS bookings and new customer implementations.
Gross Margins (Q4 2025) 53%, flat year-over-year and up 120 basis points sequentially. Financial Health gross margins improved by 65 basis points, while Patient Care gross margins declined by 75 basis points due to revenue mix and timing.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
SaaS and strategic partnerships: Bookings of $19.8 million in Q4 were supported by growing SaaS and strategic partnerships, including Microsoft and exclusive Dragon Copilot integration with TruBridge EHR.
AI-driven solutions: Focused on AI strategy with four pillars: financial health, patient care, customer service, and internal development. Examples include predictive claims denial solutions, Ambient Technology for patient care, and AI-driven support bots.
Sales pipeline growth: Sales pipeline value is the highest in 9 quarters, increasing 53% since Q3. Opportunities for larger hospitals (100+ beds) grew from 14% to 30% of the pipeline.
Recurring deals: Recurring deals now represent over 70% of the pipeline, up from 57% last summer.
Global workforce transition: Opened a new Global Capacity Center in Chennai to enhance cross-shore delivery model and improve customer retention.
Cost optimization: Achieved 350 basis points of adjusted EBITDA margin expansion in 2025 through IT, cloud operations, and vendor optimization.
Strategic review process: Engaged in a strategic review process to maximize shareholder value, with no formal guidance issued for 2026.
Credit agreement: Entered a new 5-year credit agreement with $250 million in facilities to support operations and strategic priorities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Recognition Adjustments: The company identified out-of-period adjustments related to revenue recognition, capitalized software development costs, and nonroutine transactions during the audit process. While these adjustments are noncash, they highlight potential risks in financial reporting and internal controls.
Strategic Review Process: The company is undergoing a strategic review process to maximize shareholder value, which introduces uncertainty and could impact decision-making and operational focus.
Customer Retention Challenges: Retention issues were noted in the CBO customer base due to challenges in managing onshore and offshore teams during the global workforce transition. This has acted as a headwind to the company's performance.
Global Workforce Transition: The transition to a global workforce has faced operational challenges, requiring structured transition models and oversight to mitigate risks.
Sunset of Centriq Product: The discontinuation of the Centriq product has negatively impacted revenue in the Patient Care segment, contributing to a 6.6% year-over-year decline in this area.
Financial Health of Customers: The financial health of customers has been a headwind, impacting retention and potentially affecting revenue stability.
Regulatory and Audit Risks: Material noncash misstatements were identified during the audit process, reflecting risks in governance, financial rigor, and compliance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects to achieve modest revenue growth in 2026.
Adjusted EBITDA Margin: Anticipates approximately 200 basis points of improvement in adjusted EBITDA margins in 2026.
Sales Pipeline: The sales pipeline is currently at its highest value in 9 quarters, with a 53% increase since the beginning of Q3. The pipeline is diversified across the business, with 30% of opportunities from segments with greater than 100-beds, up from 14% earlier last year. Recurring deals now represent over 70% of the pipeline, compared to 57% last summer.
Encoder Solutions: Higher-margin encoder solutions are gaining traction, with a 74% growth in the encoder pipeline driven by new business and channel partner ecosystem.
AI Strategy: The company is pursuing a comprehensive AI strategy across financial health, patient care, customer service, and internal development. This includes solutions to predict claims denials, leveraging Ambient Technology for patient care, and developing AI-driven customer support bots.
Global Delivery Model: The company opened a new Global Capacity Center in Chennai, enhancing its cross-shore global delivery model. This is expected to improve operational efficiency and customer retention.
Capital Allocation: The company plans to maintain disciplined capital allocation, including potential share buybacks and organic investments to drive stakeholder value.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buybacks: The company is constantly evaluating the best uses of capital, including share buybacks and organic investments in order to drive value for all stakeholders.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you explain how to use the new bookings metric with the annual contract value to understand revenue visibility?
A:Vinay Bassi explained that recurring revenues and some assumption of bookings conversion can be used to understand revenue visibility. Bookings can be translated into revenue using a formulaic approach, factoring in attrition.
Q:Did customer retention rates improve in Q4, and how do contract renewals in 2026 compare to 2025?
A:Christopher Fowler stated that retention rates showed modest improvement, with fewer contracts renewing in 2026 compared to 2025. He emphasized focusing on metrics like cash flow and customer communication to ensure smooth transitions.
Q:What is the timeline for the strategic review process?
A:Christopher Fowler mentioned that there is no specific timeline for the strategic review process. The Board is focused on achieving the right outcome rather than adhering to a deadline.
Q:How should we think about the conversion timing of bookings into revenue and any capacity constraints?
A:Christopher Fowler stated there are no capacity constraints, but the timing of bookings is influenced by customer schedules and contract terms. Efforts are being made to improve efficiency and better represent bookings' impact on revenue.
Q:How much incremental margin expansion opportunity remains, and are we close to peak margin?
A:Christopher Fowler and Vinay Bassi indicated that there is still room for margin expansion, driven by AI, cost optimization, and revenue mix. They do not believe they are at peak margin yet.
Q:What synergies exist from combining Patient Care and Financial Health?
A:Christopher Fowler highlighted the interconnectivity between the EHR platform and RCM services, which can fuel growth in the rural and community market.
Q:Are there any notable items from FY 2025 that won't repeat in 2026, and how does visibility compare to prior years?
A:Vinay Bassi mentioned some seasonality in revenue streams and bookings timing but did not indicate significant changes from FY 2025. Visibility remains consistent with prior years.
Q:What is the plan for pipeline to bookings conversion, and how has the new commercial leader impacted this?
A:Christopher Fowler noted that the new commercial team has improved pipeline growth and quality. Efforts are underway to smooth out the pipeline and ensure consistent bookings.
Q:Can you provide details on the financial health products for predicting claims and denials?
A:Christopher Fowler explained that the company is in the early stages of piloting homegrown technology to predict claims and denials. The goal is to reduce the arduous process of managing denials and improve efficiency.
Q:How are hospital systems' purchasing behaviors changing due to regulatory pressures?
A:Christopher Fowler observed a focus on faster ROI and integrated solutions. Customers are looking for technologies that improve provider satisfaction, patient outcomes, and revenue.
Q:What is the potential impact of the rural health fund on your business?
A:Christopher Fowler stated that the company is actively helping hospitals access the $50 billion rural health fund. They are aligning with state-specific strategies to maximize the fund's impact.
Q:Are there changes in the competitive landscape due to AI advancements?
A:Christopher Fowler noted no significant changes in the competitive landscape but emphasized the importance of ROI-driven AI projects to avoid unnecessary costs.
Q:What is the source of the 200 basis points of margin expansion opportunity?
A:Vinay Bassi explained that the margin expansion will come from a combination of global offshore transitions, cost optimization, and revenue mix improvements.
Q:What value does the partnership with RevSpring bring to customers?
A:Christopher Fowler and Vinay Bassi highlighted that the partnership enhances patient collections through digital solutions, with meaningful impact expected in 2027.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct timeline for the strategic review process, citing the need to focus on achieving the right outcome rather than adhering to a deadline.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI cash
AI pillar
AI support
AI tool
Ambient Technology
Anderson investor
Bookings contract
Chief Executive
Executive Officer
Microsoft
President Chief
Securities
TruBridge
action
adjustment
audit
care
claim
customer experience
customer service
cycle
delivery
demand
encoder
environment
expectation
financials
health
improvement
model
partner
period
point
retention
shareholder value
solution
team
technology
trajectory
transition
week
TBRG Transcript
TruBridge, Inc. (TBRG) Q4 2025 Earnings Call Transcript
Unknown4-1
The financial performance shows modest growth, with a 2% revenue increase and stable gross margins. However, the sunset of the Centriq product and flat Patient Care revenue are concerns. The Q&A reveals cautious optimism, with improvements in retention and margin expansion opportunities. The lack of a strategic review timeline and unchanged competitive landscape suggest uncertainty. Overall, the sentiment is balanced, with no strong catalysts for significant stock movement.
Source Energy Services Ltd. (SHLE:CA) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call indicates a negative sentiment due to several factors: decreased sand sales volumes and revenue, higher operating expenses, and economic uncertainties affecting completion activities. Although there's a share repurchase program, the overall financial performance is weak, with lower EBITDA and increased costs. The Q&A section reveals uncertainty in future guidance, further dampening sentiment. The revised revenue guidance and increased costs suggest a negative impact on the stock price in the short term.
TruBridge, Inc. (TBRG) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call showed mixed results: improved cash flow and debt reduction are positives, but revenue growth is modest. The Q&A highlighted delays in bookings and uncertainties in Medicaid funding. While guidance was revised, the EBITDA outlook is stronger. However, the lack of specific guidance details and potential delays temper enthusiasm. Overall, the stock is likely to remain stable, reflecting a neutral sentiment.
TruBridge, Inc. (TBRG) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call shows a generally positive outlook with several key highlights: strong customer retention, increased gross margins, and an increase in bookings. While financial health revenue remained flat, patient care revenue showed growth. Management's confidence in maintaining consistent bookings and addressing retention issues is promising. The Q&A section reveals some concerns about client attrition and potential headwinds from new legislation, but the overall sentiment remains optimistic with strategic plans for growth and efficiency improvements.
TBRG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
